Last reviewed · How we verify

NCT00975845

BioCleanse Tibialis Tendon Anterior Cruciate Ligament (ACL) Study

Completed Last updated 1 November 2021
What this trial tests

trial testing BioCleanse Tibialis tendon in Anterior Cruciate Ligament Rupture in 40 participants. Completed in 9 November 2017.

Timeline
9 November 2017
Primary endpoint
9 November 2017
9 November 2017

Quick facts

Lead sponsorRTI Surgical
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date9 November 2017
Primary completion9 November 2017
Estimated completion9 November 2017
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

RTI Surgical

Who can join

Adults 18 to 60, any sex, with Anterior Cruciate Ligament Rupture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the outcome of Anterior Cruciate Ligament (ACL) reconstruction performed using the tibialis allograft to historical outcomes of ACL reconstruction patients and to establish if any correlation exists between the age of the graft donor and the clinical outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A Prospective, Double-Blind Evaluation of Anterior Cruciate Ligament Reconstruction With Tibialis Tendon Allograft: Donor Age Does Not Alter Outcomes.
    Carter T, Norton A. · · 2023 · cited 1× · PMID 36866298 · DOI 10.1016/j.asmr.2022.11.025

Verify or expand the search:

Other recruiting trials for Anterior Cruciate Ligament Rupture

Currently open trials in the same condition.

Other RTI Surgical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00975845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing